CD44 and prostate cancer: However, several markers, including CD133, CD24, CD44, CD166, EpCAM (CD326), CXCR4 (CD184), c-kit (CD117), and among others have been identified as surface markers of CSCs isolated from glioblastoma, breast cancer, pancreatic cancer, prostate cancer, or hepatocellular carcinoma [15].